TITAN Solidifies Place for Apalutamide in Metastatic CSPC
PUBLISHED: 06 JUNE 2019
New data show efficacy for the next-generation androgen receptor inhibitor apalutamide (Erleada, Janssen) in the treatment of metastatic hormone-sensitive prostate cancer, which would be a new indication for the drug.
June 6, 2019
J-C Health Care Ltd. – Janssen Israel, Kibbutz Sheffayim 6099000, fax 09-9583636 firstname.lastname@example.org